Clinical trials: Viral Respiratory Illnesses
COVID-19
Study of Obeldesivir in Participants With COVID-19 Who Have a High Risk of Developing Serious or Severe Illness
The goal of this clinical study is to test how well the study drug, obeldesivir (GS-5245), works and how safe it is in treating coronavirus disease 2019 (COVID-19) in participants that have a higher risk of getting a serious…
- Trial name
- BIRCH (NCT05603143)
- Testing
- Obeldesivir
- Where
- 81 sites in Brazil, Bulgaria and 16 more
- Volunteers
- 468 people
- Sponsor
- Gilead Sciences
Healthy Participants
A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).
The purpose of the study is to learn about the safety and effects of a combined vaccine for RSV and COVID-19 when given with a seasonal flu vaccine or when given alone.
- Trial name
- NCT05886777
- Testing
- Combination [RSVpreF+BNTb162b2], Bivalent BNT162b2 (original/Omi BA.4/BA.5), RSVpreF
- Where
- 37 sites in United States
- Volunteers
- 1,142 people, healthy volunteers welcome
- Sponsor
- Pfizer
Participants Less Than 12 Months of Age With RSV Illness
A Study to Evaluate a Single Intramuscular Dose of Motavizumab to Treat Children With Respiratory Syncytial Virus (RSV) Illness
This was a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to determine the effect of a single 30 mg/kg intramuscular (IM) dose of motavizumab on viral load and motavizumab levels in the upper respiratory…
- Trial name
- NCT00435227
- Testing
- Motavizumab
- Where
- 31 sites in United States
- Volunteers
- 12 people
- Sponsor
- MedImmune LLC
COVID-19
VA CoronavirUs Research and Efficacy Studies-1
The purpose of this study is to determine if treatment with convalescent plasma improves the clinical outcomes of Veterans who are hospitalized and require supplemental oxygen due to COVID-19.
- Trial name
- VACURES-1 (NCT04539275)
- Testing
- Convalescent Plasma
- Where
- 24 sites in United States, Puerto Rico
- Volunteers
- 75 people
- Sponsor
- VA Office of Research and Development
Viral Infection, Acute Respiratory Infection
Urgent Care Management of Respiratory Illness Enabled With Novel Testing Pathway
Rapid diagnosis and precise treatment have become possible with multiplex polymerase chain reaction (PCR) panels that can identify a variety of causative agents of acute respiratory illnesses such as bacterial and viral…
- Conditions
- Viral Infection, Acute Respiratory Infection, Upper Resp Tract Infection
- Trial name
- URGENT (NCT05467007)
- Testing
- BioFire® Respiratory Panel 2.1-EZ
- Where
- 2 sites in United States
- Volunteers
- 360 people
- Sponsor
- Andrew Meltzer
COVID-19
EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19
The purpose of this study is to determine whether PF-07321332/ritonavir is safe and effective for the treatment of adults who are ill with COVID-19 and do not need to be in the hospital, but are at an increased risk of developing…
- Trial name
- NCT04960202
- Testing
- PF-07321332, Ritonavir
- Where
- 201 sites in United States, Argentina and 18 more
- Volunteers
- 2,091 people
- Sponsor
- Pfizer
COVID-19
A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness
The purpose of this study is to measure how well LY3819253 and LY3832479 work against the virus that causes COVID-19. LY3819253 and LY3832479 will be given to participants with early symptoms of COVID-19.
- Trial name
- BLAZE-1 (NCT04427501)
- Testing
- LY3819253, LY3832479, LY3853113
- Where
- 12 sites in United States
- Volunteers
- 3,307 people
- Sponsor
- Eli Lilly and Company
COVID-19, Cardiorespiratory Failure
Lift Mobile Mindfulness for COVID-19 Distress Symptoms
This is a randomized clinical trial (RCT) nested within the NIH PETAL Network's COVID cohort study (BLUE CORAL [Biology and Longitudinal Epidemiology: COVID Observational Study]) of patients hospitalized for COVID-19-related…
- Trial name
- LIFTCOVID (NCT04581200)
- Testing
- Lift
- Where
- 4 sites in United States
- Volunteers
- 56 people
- Sponsor
- Duke University
Influenza, Seasonal Influenza
First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV in Healthy Adults
Background: Influenza (flu) is a contagious respiratory illness. It is caused by influenza viruses that infect the nose, throat, and sometimes the lungs. Vaccines are given to teach the body to prevent or fight infection.
- Trial name
- NCT04896086
- Testing
- VRC-GENADJ0110-AP-NV (Adjuplex), Flucelvax, VRC-FLUMOS0111-00-VP (FluMos-v1)
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)